Technical Analysis for BIIB - Biogen Idec Inc.
|Grade||Last Price||% Change||Price Change|
BIIB closed up 0.24 percent on Wednesday, November 22, 2017, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Up||Down||Flat|
|See historical BIIB trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 22||NR7||Range Contraction||0.00%|
|Nov 22||Bollinger Band Squeeze||Range Contraction||0.00%|
|Nov 21||Bollinger Band Squeeze||Range Contraction||0.24%|
|Nov 20||Bollinger Band Squeeze||Range Contraction||0.11%|
|Nov 20||MACD Bearish Signal Line Cross||Bearish||0.11%|
|Nov 17||MACD Bullish Signal Line Cross||Bullish||-1.33%|
|Nov 17||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-1.33%|
|Nov 10||Doji - Bullish?||Reversal||-0.21%|
|Nov 8||NR7||Range Contraction||-0.89%|
|Nov 8||Narrow Range Bar||Range Contraction||-0.89%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BIIB news...
|52 Week High||348.84|
|52 Week Low||244.28|
|200-Day Moving Average||288.5559|
|50-Day Moving Average||319.467|
|20-Day Moving Average||311.7955|
|10-Day Moving Average||311.218|
|Average True Range||6.6222|
|Chandelier Exit (Long, 3 ATRs )||301.2434|
|Chandelier Exit (Short, 3 ATRs )||321.6766|
|Upper Bollinger Band||317.2125|
|Lower Bollinger Band||306.3785|
|Percent B (%b)||0.32|
|MACD Signal Line||-2.6144|
|Market Cap||65.51 Billion|
|Num Shares||211 Million|
|Price-to-Earnings (P/E) Ratio||20.33|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||315.74|
|Resistance 3 (R3)||315.52||313.31||314.75|
|Resistance 2 (R2)||313.31||311.80||313.43||314.42|
|Resistance 1 (R1)||311.56||310.87||312.44||311.78||314.09|
|Support 1 (S1)||307.60||307.84||308.48||307.82||305.51|
|Support 2 (S2)||305.39||306.91||305.51||305.18|
|Support 3 (S3)||303.64||305.39||304.85|
|Support 4 (S4)||303.86|